ANI Pharmaceuticals Inc (ANIP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.37 Million) by net assets ($540.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ANI Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
ANI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ANI Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ANI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NP3 Fastigheter AB
ST:NP3
|
0.016x |
|
Twenty One Capital, Inc.
NYSE:XXI
|
N/A |
|
Bausch Health Companies Inc
TO:BHC
|
-0.213x |
|
Karooooo Ltd
JSE:KRO
|
0.151x |
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
0.031x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
McGraw Hill, Inc.
NYSE:MH
|
0.398x |
|
Five-Star Business Finance Limited
NSE:FIVESTAR
|
0.002x |
Annual Cash Flow Conversion Efficiency for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of ANI Pharmaceuticals Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see ANI Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $540.72 Million | $185.22 Million | 0.343x | +129.30% |
| 2024-12-31 | $428.53 Million | $64.02 Million | 0.149x | -42.54% |
| 2023-12-31 | $457.60 Million | $118.96 Million | 0.260x | +382.05% |
| 2022-12-31 | $338.54 Million | $-31.20 Million | -0.092x | -1095.33% |
| 2021-12-31 | $358.74 Million | $3.32 Million | 0.009x | -88.13% |
| 2020-12-31 | $195.70 Million | $15.27 Million | 0.078x | -63.62% |
| 2019-12-31 | $212.79 Million | $45.63 Million | 0.214x | -36.93% |
| 2018-12-31 | $197.26 Million | $67.07 Million | 0.340x | +50.74% |
| 2017-12-31 | $174.76 Million | $39.42 Million | 0.226x | +39.29% |
| 2016-12-31 | $169.65 Million | $27.47 Million | 0.162x | +50.16% |
| 2015-12-31 | $160.08 Million | $17.26 Million | 0.108x | -31.58% |
| 2014-12-31 | $139.78 Million | $22.03 Million | 0.158x | +217.73% |
| 2013-12-31 | $40.96 Million | $-5.48 Million | -0.134x | +85.08% |
| 2012-12-31 | $28.18 Million | $-25.28 Million | -0.897x | +29.11% |
| 2011-12-31 | $37.82 Million | $-47.87 Million | -1.266x | +39.55% |
| 2010-12-31 | $19.15 Million | $-40.10 Million | -2.094x | -79.87% |
| 2009-12-31 | $15.83 Million | $-18.43 Million | -1.164x | -3.62% |
| 2008-12-31 | $13.83 Million | $-15.54 Million | -1.124x | -4613.67% |
| 2007-12-31 | $29.73 Million | $739.99K | 0.025x | +109.00% |
| 2006-12-31 | $18.07 Million | $-5.00 Million | -0.277x | +77.28% |
| 2005-12-31 | $6.82 Million | $-8.30 Million | -1.217x | -85.52% |
| 2004-12-31 | $15.92 Million | $-10.44 Million | -0.656x | -3.15% |
| 2003-12-31 | $8.68 Million | $-5.52 Million | -0.636x | +25.81% |
| 2002-12-31 | $4.62 Million | $-3.96 Million | -0.857x | -90.38% |
| 2001-12-31 | $4.05 Million | $-1.82 Million | -0.450x | +70.17% |
| 2000-12-31 | $2.13 Million | $-3.21 Million | -1.509x | -360.05% |
| 1999-12-31 | $5.45 Million | $-1.79 Million | -0.328x | +71.62% |
| 1998-12-31 | $2.63 Million | $-3.04 Million | -1.156x | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more